SE9201573D0 - Use of igf-1 - Google Patents

Use of igf-1

Info

Publication number
SE9201573D0
SE9201573D0 SE9201573A SE9201573A SE9201573D0 SE 9201573 D0 SE9201573 D0 SE 9201573D0 SE 9201573 A SE9201573 A SE 9201573A SE 9201573 A SE9201573 A SE 9201573A SE 9201573 D0 SE9201573 D0 SE 9201573D0
Authority
SE
Sweden
Prior art keywords
pct
igf
treatment
medicament
sec
Prior art date
Application number
SE9201573A
Other languages
English (en)
Inventor
D B Dunger
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9201573A priority Critical patent/SE9201573D0/sv
Publication of SE9201573D0 publication Critical patent/SE9201573D0/sv
Priority to AT93910528T priority patent/ATE207758T1/de
Priority to PCT/SE1993/000425 priority patent/WO1993023071A1/en
Priority to EP93910528A priority patent/EP0613376B1/en
Priority to US08/175,404 priority patent/US5466670A/en
Priority to JP5520132A priority patent/JPH06509361A/ja
Priority to DE69331045T priority patent/DE69331045T2/de
Priority to AU40988/93A priority patent/AU669894B2/en
Priority to NZ252359A priority patent/NZ252359A/en
Priority to CA002112358A priority patent/CA2112358A1/en
Priority to NO940180A priority patent/NO940180L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
SE9201573A 1992-05-19 1992-05-19 Use of igf-1 SE9201573D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1
CA002112358A CA2112358A1 (en) 1992-05-19 1993-05-14 Use of igf-1
US08/175,404 US5466670A (en) 1992-05-19 1993-05-14 Use of IGF-1
PCT/SE1993/000425 WO1993023071A1 (en) 1992-05-19 1993-05-14 Use of igf-1
EP93910528A EP0613376B1 (en) 1992-05-19 1993-05-14 Use of igf-1
AT93910528T ATE207758T1 (de) 1992-05-19 1993-05-14 Verwendung von igf-1
JP5520132A JPH06509361A (ja) 1992-05-19 1993-05-14 インシュリン様増殖因子の用法
DE69331045T DE69331045T2 (de) 1992-05-19 1993-05-14 Verwendung von igf-1
AU40988/93A AU669894B2 (en) 1992-05-19 1993-05-14 Use of IGF-1
NZ252359A NZ252359A (en) 1992-05-19 1993-05-14 Use of igf-1
NO940180A NO940180L (no) 1992-05-19 1994-01-18 Anvendelse av IGF-I

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1

Publications (1)

Publication Number Publication Date
SE9201573D0 true SE9201573D0 (sv) 1992-05-19

Family

ID=20386281

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9201573A SE9201573D0 (sv) 1992-05-19 1992-05-19 Use of igf-1

Country Status (11)

Country Link
US (1) US5466670A (sv)
EP (1) EP0613376B1 (sv)
JP (1) JPH06509361A (sv)
AT (1) ATE207758T1 (sv)
AU (1) AU669894B2 (sv)
CA (1) CA2112358A1 (sv)
DE (1) DE69331045T2 (sv)
NO (1) NO940180L (sv)
NZ (1) NZ252359A (sv)
SE (1) SE9201573D0 (sv)
WO (1) WO1993023071A1 (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US20020049422A1 (en) * 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
US20060088575A1 (en) * 1994-03-31 2006-04-27 Brewitt Barbara A Homeopathic preparations of purified growth factors and purified growth hormones and associated carriers
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
IL143866A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
CA2369451C (en) * 1999-04-08 2009-09-22 Genentech, Inc. Composition based on oppositely-charged polypeptides
US6040292A (en) * 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
US6984405B1 (en) 2000-12-15 2006-01-10 Naturalendo Tech Co., Ltd. Compositions for inducing secretion of insulin-like growth factor-1
DK1358209T3 (da) * 2001-02-09 2007-05-07 Genentech Inc Krystallisering af IGF-1
US7071300B2 (en) 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
AU2005279758A1 (en) * 2004-08-30 2006-03-09 Tercica, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
EP2763692A2 (en) * 2011-10-06 2014-08-13 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) * 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes

Also Published As

Publication number Publication date
NZ252359A (en) 1997-05-26
CA2112358A1 (en) 1993-11-25
JPH06509361A (ja) 1994-10-20
DE69331045D1 (de) 2001-12-06
EP0613376B1 (en) 2001-10-31
EP0613376A1 (en) 1994-09-07
WO1993023071A1 (en) 1993-11-25
NO940180D0 (no) 1994-01-18
AU4098893A (en) 1993-12-13
US5466670A (en) 1995-11-14
NO940180L (no) 1994-01-18
ATE207758T1 (de) 2001-11-15
DE69331045T2 (de) 2002-03-21
AU669894B2 (en) 1996-06-27

Similar Documents

Publication Publication Date Title
SE9201573D0 (sv) Use of igf-1
MX9604635A (es) Tratamiento del sindrome de insensibilidad parcial a la hormona del crecimiento.
UA27874C2 (uk) Препарат інсуліну людини, спосіб одержання препарату, спосіб лікування цукрового діабету
ES2043890T3 (es) Nuevo uso medico.
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
ZA885242B (en) Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69226835T2 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
ES2183952T3 (es) Tratamiento de diabetes tipo ii con dosis elevadas de tripicolinato cromico.
CA2196174A1 (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
ATE271880T1 (de) Methoden zur behandlung von diabetes
GB2223168B (en) Pharmaceutical composition comprising inositoltrisphosphate for the treatment of complications of diabetes
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
ATE228007T1 (de) Verwendung von wachstumshormone
DE69227921D1 (de) Herstellung von Proteinen mittels Protein 7B2
DE69221725T2 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
DK155491D0 (da) Behandling af patienter med kronisk leversygdom
PT914148E (pt) Tratamento do sindroma de insensibilidade parcial a hormona de crescimento
ZA905422B (en) Substituted 2-imidazolines and preparation and use thereof
ATE209042T1 (de) Verwendung des wachstumshormons in mitteln zur behandlung der insulinresistenz im herzen
MX9804749A (es) Uso de compuestos para reducir la glucosa en sangre y/o inhibir la secrecion, circulacion o efecto de los peptidos antagonizantes de la insulina.
DE69218544T2 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
DE60120371D1 (de) Verwendung von wachstumshormon in niederen dosen